Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients

Ann Rheum Dis. 2023 Nov;82(11):1499-1501. doi: 10.1136/ard-2023-223919. Epub 2023 Jun 6.
No abstract available

Keywords: Dermatomyositis; Glucocorticoids; Outcome Assessment, Health Care; T-Lymphocyte subsets.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Dermatomyositis* / complications
  • Dermatomyositis* / drug therapy
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Lung Diseases, Interstitial* / drug therapy
  • Lung Diseases, Interstitial* / etiology
  • Piperidines / therapeutic use
  • Prognosis
  • Pyrimidines / therapeutic use
  • Retrospective Studies

Substances

  • tofacitinib
  • Piperidines
  • Pyrimidines
  • Interferon-Induced Helicase, IFIH1
  • Autoantibodies